The Renin-Angiotensin System Modulates Inflammatory Processes in Atherosclerosis: Evidence from Basic Research and Clinical Studies

被引:91
作者
Montecucco, Fabrizio [1 ]
Pende, Aldo [2 ]
Mach, Francois [1 ]
机构
[1] Univ Hosp Geneva, Fdn Med Res, Div Cardiol, CH-1211 Geneva, Switzerland
[2] Univ Genoa, Dept Internal Med, Clin Internal Med 1, I-16132 Genoa, Italy
关键词
CONVERTING-ENZYME-INHIBITION; CORONARY-ARTERY-DISEASE; II-RECEPTOR BLOCKERS; MONOCYTE CHEMOATTRACTANT PROTEIN-1; FACTOR-KAPPA-B; C-REACTIVE PROTEIN; ACE-INHIBITION; CARDIOVASCULAR EVENTS; ENDOTHELIAL DYSFUNCTION; TYPE-2; RECEPTOR;
D O I
10.1155/2009/752406
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Recent evidence shows that the renin-angiotensin system is a crucial player in atherosclerotic processes. The regulation of arterial blood pressure was considered from its first description of the main mechanism involved. Vasoconstriction (mediated by angiotensin II) and salt and water retention (mainly due to aldosterone) were classically considered as pivotal proatherosclerotic activities. However, basic research and animal studies strongly support angiotensin II as a proinflammatory mediator, which directly induces atherosclerotic plaque development and heart remodeling. Furthermore, angiotensin II induces proatherosclerotic cytokine and chemokine secretion and increases endothelial dysfunction. Accordingly, the pharmacological inhibition of the renin-angiotensin system improves prognosis of patients with cardiovascular disease even in settings of normal baseline blood pressure. In the present review, we focused on angiotensin-convertingenzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), and renin inhibitors to update the direct activities of the renin-angiotensin systemin inflammatory processes governing atherosclerosis. Copyright (C) 2009 Fabrizio Montecucco et al.
引用
收藏
页数:13
相关论文
共 143 条
[1]   Angiotensin-converting enzyme inhibition and vascular remodeling in coronary artery disease [J].
Adams, KF .
CORONARY ARTERY DISEASE, 1998, 9 (10) :675-684
[2]  
Akishita M, 2000, PHYSIOL GENOMICS, V2, P13
[3]   Angiotensin converting enzyme inhibitor restrains inflammation-induced vascular injury in mice [J].
Akishita, M ;
Shirakami, G ;
Iwai, M ;
Wu, L ;
Aoki, M ;
Zhang, LN ;
Toba, K ;
Horiuchi, M .
JOURNAL OF HYPERTENSION, 2001, 19 (06) :1083-1088
[4]   Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study) [J].
Anderson, TJ ;
Elstein, E ;
Haber, H ;
Charbonneau, F .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 35 (01) :60-66
[5]   CX3CR1 receptor is up-regulated in monocytes of coronary artery diseased patients: Impact of pre-inflammatory stimuli and renin-angiotensin system modulators [J].
Apostolakis, Stavros ;
Krambovitis, Elias ;
Vlata, Zaharenia ;
Kochiadakis, Georgios E. ;
Baritaki, Stavroula ;
Spandidos, Demetrios A. .
THROMBOSIS RESEARCH, 2007, 121 (03) :387-395
[6]   Update on tissue renin-angiotensin systems [J].
Bader, Michael ;
Ganten, Detlev .
JOURNAL OF MOLECULAR MEDICINE-JMM, 2008, 86 (06) :615-621
[7]  
BECKER RHA, 1991, J CARDIOVASC PHARM, V18, pS110, DOI 10.1097/00005344-199100182-00023
[8]   Anti-atherosclerotic properties of telmisartan in advanced atherosclerotic lesions in apolipoprotein E deficient mice [J].
Blessing, Erwin ;
Preusch, Michael ;
Kranzhoefer, Roger ;
Kinscherf, Ralf ;
Marx, Nikolaus ;
Rosenfeld, Michael E. ;
Isermann, Berend ;
Weber, Christian M. ;
Kreuzer, Joerg ;
Graefe, Julia ;
Katus, Hugo A. ;
Bea, Florian .
ATHEROSCLEROSIS, 2008, 199 (02) :295-303
[9]   Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion [J].
Brand, K ;
Page, S ;
Rogler, G ;
Bartsch, A ;
Brandl, R ;
Knuechel, R ;
Page, M ;
Kaltschmidt, C ;
Baeuerle, PA ;
Neumeier, D .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 97 (07) :1715-1722
[10]  
Braunwald E, 2004, NEW ENGL J MED, V351, P2058